Traws Pharma, Inc. TRAW
0.25 USD -0.03 (-10.36%)
At closeNov 13, 2026, 5:36 PM EST
0.27 +0.02 +8.29%
After hours · Nov 13, 5:36 PM ET
0.23 Day range 0.29
0.22 52-week range 3.23
- YTD
- -77.79%
- 1 year
- -85.82%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma Inc. (NASDAQ:TRAW) announced final Phase 2a clinical data for its investigational oral COVID-19 therapy ratutrelvir alongside completed bridging and toxicology studies for its…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.
benzinga.com Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28…
globenewswire.com Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® Ratutrelvir , a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID ® , with no viral rebound through Day…- benzinga.com Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments"…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience…
benzinga.com Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…
benzinga.com HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.- benzinga.com Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of…
benzinga.com Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2M Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This prospectus covers our offer and sale from time to time of any combination of common stock, preferred…- benzinga.com Traws Pharma Announces That An Updated Toxicology Data Package Is Being Developed In Response To The UK MHRA's Information Requirements For Planned Testing Of Tivoxavir Marboxil In A Phase 2a Human Influenza Challenge Study The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. "Based upon recent feedback and further guidance from the MHRA, we believe our updated data package…
benzinga.com This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.- benzinga.com HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price Target HC Wainwright & Co. analyst Brandon Folkes downgrades Traws Pharma (NASDAQ:TRAW) from Buy to Neutral and announces $1 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.
benzinga.com Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply agreement and resolving IP disputes. Other gainers include VS Media Holdings (VSME), Freecast Inc…
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
benzinga.com Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary…- benzinga.com HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Buy and maintains $8 price target.
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 66.46 percent increase over losses of $(1.58)…
benzinga.com Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World Hantavirus outbreak on a cruise ship sparks alarm as Schumer blames CDC cuts, warning weakened disease surveillance and calling for urgent reforms.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak Traws Pharma shares jump after the company advanced hantavirus antiviral candidates amid global monitoring of a cruise ship outbreak.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Traws Pharma Prices $10M PIPE At $1.673/Share For 5.98M Shares, Issues Warrants For Up To 29.9M Shares With $50M Additional Upside Potential Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the "Company") announced the pricing of an offering (the "Private Placement") of…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Traws Pharma Completed Clinical Analysis Of Its 90-patient, Open-label Phase 2 Study Of Ratutrelvir Versus Paxlovid For Mild-to-moderate Covid-19 Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution;…- benzinga.com Traws Pharma Files Clinical Trial Application With FDA For Tivoxavir Marboxil, a Single Oral Tablet Administered For Influenza, Full Study Enrollment Expected In January 2026 IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.
benzinga.com Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026 The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/ritonavir) and evaluated patient-reported symptom outcomes, safety, and real-world usability. A separate…
benzinga.com This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com HC Wainwright & Co. Initiates Coverage On Traws Pharma with Buy Rating, Announces Price Target of $8 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Traws Pharma (NASDAQ:TRAW) with a Buy rating and announces Price Target of $8.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session